LRRC32 & TGF-beta 1產(chǎn)品信息
物種：Human / Mouse / Cynomolgus
屬性：Protein
標記：Unconjugated
分子別名（Synonym）
LRRC32 & TGF-beta 1,LRRC32&TGFB1
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.
LRRC32 & TGF-beta 1分子背景
GARP (LRRC32) is a transmembrane protein that binds latent-TGF-β1 and tethers it on the Treg surface. and has been proved to promote the activation and secretion of transforming growth factor β (TGF-β). The expression of GARP is highly on the surface activated Tregs and increases the suppressive function of Tregs. Additionally, GARP can bind to latent transforming growth factor β (TGF-β), thus promoting secretion and activation of TGF-β. TGF-β plays a critical rule for homeostasis and function of Tregs. Notably, it has been also observed that fibroblasts and endothelial cell lines that express GARP/latent TGF-β1 complexes do not activate TGF-β1. However, it cannot be excluded that specific stimuli are required to trigger TGF-β1 activation from complexes on the surface of these cell types.
關(guān)鍵字： LRRC32 & TGF-beta 1;LRRC32;TGF-beta 1;LRRC32蛋白;TGF-beta 1蛋白;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。